Phase II, placebo-controlled trial of SAGE-718 on cognitive function in participants with Huntington’s disease
C
Christopher James
Primary Investigator
Administratively Closed
25 years - 65 years
All
Phase
2
5 participants needed
2 Locations
Brief description of study
Who is Eligible
- Ages 25-65
- Diagnosis of Huntington’s disease
- Able to swallow pills and liquids
- No history of cancer within last 12 months
- No current substance or alcohol abuse (including THC)
- No history of stroke or head injury requiring hospitalization
What is Involved
- In person at IUH Neuroscience Center
Daily oral medication over 12 weeks with participation over a total of 4 months.
Compensation
- Compensation available via payment card for each completed appointment
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Huntingtons disease
-
Age: 25 years - 65 years
-
Gender: All
Updated on
06 Feb 2025.
Study ID: NEUR-SAGE-718-CIH-201, 14964, TX11533
